Oncology Archives - Page 5 of 23

Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer

Authors: J Garside, Q Shen, B Westermayer, M van de Ven, S Kroep, V Chirikov, I Juhasz-Böss Published: Clinical Therapeutics, 2023 View publication Purpose Advanced/recurrent endometrial cancer is associated with poor long-term...

Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective

Authors: N Dhanji, T Cristina Decimoni, M T D Dyer , J R May, G van de Wetering, S Petersohn, K Nickel, A Silva, D Q B Muniz, A P C D...

Retrospective comparison of survival projections for CAR T-Cell therapies in large B-Cell lymphoma

Authors: E F P Peterse, E J M Verburg-Baltussen, A Stewart, F F Liu, C Parker, M Treur, B Malcolm, S L Klijn Published: PharmacoEconomics – open, 2023 View publication Background Durable...

A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program

Authors: C Palmieri, A Musson, C Harper-Wynne, D Wheatley, G Bertelli, I R Macpherson, M Nathan, E McDowall, A Bhojwani, Mark Verrill, J Eva, C Doody, R Chowdhury Published: British Journal of...

The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey

Authors: E A Szamreta, W-J Wang, R Shah, S Corman, M Monberg Published: Future Oncology, 2023 View publication Aim To evaluate the economic and humanistic burden of ovarian cancer in the USA. ...

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma

Authors: S Petersohn, B McGregor, SL Klijn, JR May, F Ejzykowicz, M Kurt, M Dyer, B Malcolm, S Branchoux, K Nickel, S George, S Kroep Published: Journal of comparative effectiveness research, 2023...

Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocar

Authors: D Lin, H Nguyen, R Shah, Y Qiao, J Hartman, R Sugarman Published: Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023 View...

Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies. Health technology assessment (HTA) agencies have long required evidence of long-term survival and...

Cost-effectiveness of Nivolumab plus Ipilimumab for the first-line treatment of intermediate/poor-risk advanced and/or metastatic renal cell carcinoma in Switzerland

Authors: E Çakar, C Oniangue-Ndza, R P Schneider, S L Klijn, U M Vogl, C Rothermundt, J R May Published: PharmacoEconomics – open, 2023 View publication Objective This study assessed the cost-effectiveness...

News